Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
43 Clinical Trials near Boston, MA
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
AL001 for Pharmacokinetics
Boston, MassachusettsThe goal of this clinical trial is to assess the safety and effects of a crystalized form of lithium, AL001, when compared to commonly used Lithium Carbonate in healthy volunteers. The main questions this study aims to answer are:
How safe and effective is AL001 when compared to Lithium Carbonate? How is AL001 broken down in the brain and body compared to Lithium Carbonate?
Participants will be asked to:
* Take both the study drug (AL001) and Lithium Carbonate each for a period of 14 days
* Stay overnight at MGH's research unit for two separate 2-week periods
* Participate in two separate 24 hour periods of multiple MRIs and blood draws
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 64
Sex:All
6 Participants Needed
NAM + NMN for Healthy Adults
Boston, MassachusettsWe are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
32 Participants Needed
Vaccine Regimen for HIV Prevention
Boston, MassachusettsThis is a partially randomized, open-label phase 1 study to evaluate the safety and immunogenicity of a priming regimen of 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum followed by boosts with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum.
The primary hypothesis is that the boosting with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum will further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum.
426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum has been tested in HVTN 301 previously, whereas the HxB2.WT.Core-C4b will be first-in-human (FIH).
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
42 Participants Needed
Palovarotene for Liver Disease
Boston, MassachusettsThe main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function.
The study will also assess the safety and tolerability of the single dose of palovarotene.
Participants will be enrolled in stages and divided into three groups based on their liver function:
* Group 1: Healthy participants with normal liver function
* Group 2: Participants with moderate liver impairment
* Group 3: Participants with severe liver impairment (only enrolled if Group 2 results are safe and acceptable)
Blood samples will be taken to assess how the drug binds to proteins in the blood. Participants will undergo various safety checks and procedures. Participants will stay in the clinical unit until Day 5 for these assessments and will return on Day 10 for a final visit.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 70
Sex:All
32 Participants Needed
Suzetrigine for Pain
Woburn, MassachusettsThe purpose of this study is to evaluate the sensory attributes (basic tastes, aroma, texture, mouthfeel) of SUZ SDD and assess the impact of the dose on the sensory attributes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:25 - 80
Sex:All
10 Participants Needed
MIB-725 Safety Study
Boston, MassachusettsThis is a single center, open label (i.e. participants and study staff will not be masked to the intervention) single ascending dose study to evaluate the safety, tolerability, pharmaokinetics and pharmacodynamics of MIB-725 in community dwelling, healthy adults. Up to 4 successive groups (cohorts) of 8 subjects each will be enrolled in this trial.
This study will determine the safety and tolerability of orally administered single ascending (increasing) doses (100, 200, 400, and 800 mg) of MIB-725 in healthy adults. The safety will be assessed by evaluating physical examination that includes an external eye examination, vital signs, adverse events, and changes in blood counts, EKG, urinalysis, coagulation measures, and blood chemistries, including but not limited to blood glucose, electrolytes, creatinine, liver function tests, uric acid, and creatine kinase.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Cancer, Heart Failure, Others
Must Not Be Taking:Barbiturates, Benzodiazepines, Opiates, Others
32 Participants Needed
Flu Vaccine for Influenza
Boston, MassachusettsThe purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
1158 Participants Needed
Ketamine for Depression
Boston, MassachusettsSubanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression and associated suicidality but its exact mechanism of remains uncertain. This study will use a novel approach to elucidate KET's effects on the molecular/ gene expression pathways in living neurons obtained from the olfactory epithelium and correlate the changes to rapid improvement in depression via changes in the brain connectome. The study will identify the molecular targets and pathways involved in KET'S mechanism of rapid clinical action and pave the way for development of novel, more efficacious, and safer therapeutic agents.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 50
Sex:All
120 Participants Needed
Contact Lens Wear for Fuchs' Dystrophy
Boston, MassachusettsThe purpose of this study is to determine the difference in the cornea's response to contact lens placement between healthy and unhealthy eyes. The amount of corneal swelling (corneal thickness) between normal and FECD patients before and after a stress test will be measured and compared.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Others
20 Participants Needed
mRNA Vaccines for HIV Prevention
Boston, MassachusettsThis is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are:
1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors,
2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional mutations needed for broadly neutralizing antibody (bnAb) development, and
3. these mRNA-LNPs will be safe and well tolerated among individuals living without HIV.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Diabetes, Immunodeficiency, Others
Must Not Be Taking:Glucocorticoids, Immunoglobulin, Antiseizure, Others
48 Participants Needed
Combination Vaccine for COVID-19 and Flu
Malden, MassachusettsStudy VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, and RIV + rC19 study groups to control for the number of injections and to maintain observer blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle.
Study details include:
* The study duration will be approximately 12 months
* Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on Day(D) 01
* Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose)
* The visit frequency for participants will be D01 and D30, and D09-D366 (telephone call)
Number of Participants:
Approximately 980 participants are expected to be randomized.
Stay on current meds
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Bleeding Disorder, Stroke, Others
Must Not Be Taking:Immunosuppressants, Anticoagulants
980 Participants Needed
BMS-986470 for Sickle Cell Disease
Boston, MassachusettsThe purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe VOCs, Acute Chest Syndrome, Others
Must Be Taking:Hydroxyurea
184 Participants Needed
IMNN-101 Vaccine for COVID-19
Boston, MassachusettsThis is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
74 Participants Needed
Buprenorphine for Opioid Use Disorder
Boston, MassachusettsThis is a human laboratory-based, randomized, cross-over study in which buprenorphine will be administered to healthy volunteers (n=22) in 3 separate inpatient 2-night visits, at least 1 week apart. At each visit, the participant will receive a single dose buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO. Participants will be given naltrexone to produce opioid blockade to eliminate the risk for opioid dependence in individuals without OUD. Timed blood samples will be collected up to 24 hours.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Chronic Pain, Others
Must Not Be Taking:Opioids, CYP34A Inducers
22 Participants Needed
Vaccines for HIV Prevention
Boston, MassachusettsThe goal of this clinical trial is to test 16055 NFL delta Gly4 Env protein trimer and Trimer 4571 combined with 3M-052-AF + Alum adjuvant and Ad4-Env145NFL viral particles as heterologous prime-boost regimens in adult participants without HIV.
The main question\[s\] it aims to answer are:
* Are these vaccine regimens safe and well tolerated?
* Are the prime-boost vaccine regimens that include Ad4-Env145NFL and Trimer 4571 as heterologous boosts going contribute to the development of B-cell and antibody responses?
Participants will attend scheduled study visits to receive their vaccine and will record symptoms on a daily eDiary.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
45 Participants Needed
RM-718 for Hypothalamic Obesity
Boston, MassachusettsThis trial tests RM-718, an injection, in adults with obesity and patients with hypothalamic obesity. It aims to check if the drug is safe and how well people can tolerate it.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:12 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Psychiatric Disorders, Renal Disease, Others
Must Not Be Taking:Anti-obesity Medications
120 Participants Needed
RCT2100 for Cystic Fibrosis
Boston, MassachusettsThis is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Smoking, Hepatic Impairment, Others
Must Not Be Taking:CFTR Modulators
158 Participants Needed
HIV Vaccine + Adjuvant for HIV Prevention
Boston, MassachusettsHVTN 144 is a phase 1 clinical trial to being conducted to evaluate the safety and immunogenicity of an HIV envelope trimer, N332-GT5 gp140, adjuvanted with saponin/MPLA nanoparticles (SMNP) in adult participants without HIV. The study aims to evaluate the safety and tolerability of N332-GT5 gp140 adjuvanted with SMNP in adult volunteers without HIV and in overall good health, including identifying a safe and tolerable dose, route, and schedule of administration of the novel adjuvant SMNP. The study also aims to evaluate the induction of BG18-class immunoglobulin G (IgG) B-cell responses in memory B cells by the study regimens and compare the responses between the different groups.
HVTN 144 will be conducted in 2 parts with 84 volunteers without HIV and in overall good health, aged 18 to 55 years. The study duration is 22 months which includes 8 months for enrollment, planned safety holds, follow-up, and Adverse Event of Special Interest (AESI) health contact 1 year after last vaccination.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
57 Participants Needed
VIR-1388 Vaccine for HIV Prevention
Boston, MassachusettsThis trial is testing a new treatment called VIR 1388 in healthy adults aged 18 to 55 who do not have HIV. The study aims to see if the treatment is safe, what side effects it might cause, and how well it helps the immune system. Participants will be monitored closely for any reactions.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
95 Participants Needed
mRNA-1608 Vaccine for Genital Herpes
Boston, MassachusettsThis trial is testing a new vaccine called mRNA-1608 in people who frequently get genital herpes. The vaccine aims to help their immune system recognize and fight the herpes virus, which could reduce how often and how severely they get outbreaks.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55
Sex:All
365 Participants Needed
HIV-1 Envelope Trimer Vaccine for HIV Prevention
Boston, MassachusettsThis trial tests a new two-step HIV treatment in humans for the first time. The first shot introduces a protein to help the immune system recognize HIV. The second shot uses mRNA to boost the immune response by teaching the body to make a part of the virus. The goal is to produce antibodies that can neutralize HIV.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
36 Participants Needed
mRNA Vaccines for Lyme Disease
Brookline, MassachusettsThis trial is testing two different vaccines for Lyme disease in healthy adults. One vaccine targets seven parts of the bacteria, and the other targets just one. The vaccines use mRNA to teach the immune system to recognize and fight the bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
807 Participants Needed
SPG302 for ALS
Boston, MassachusettsThe first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
112 Participants Needed
Synthetic DNA + Protein Boosts Vaccine for HIV Protection
Boston, MassachusettsThis is an open-label study to examine the safety and immunogenicity of synthetic DNAs encoding NP-GT8 and IL-12 with or without a TLR-agonist-adjuvanted Env Trimer 4571 boost in adults without HIV. The primary hypothesis is that vaccination with a recombinant DNA vaccine encoding a germline-targeting epitope followed by a trimeric protein boost will be safe and immunogenic.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
46 Participants Needed
mRNA EBV Vaccine for EBV Infection
Brookline, MassachusettsThis trial tests the safety of a new vaccine called mRNA-1195 in healthy adults. The study is split into two parts based on whether participants have been exposed to Epstein-Barr Virus. The vaccine works by teaching the body to recognize and fight the virus.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
474 Participants Needed
CH505 TF chTrimer Vaccine for HIV Prevention
Boston, MassachusettsThis trial tests a new vaccine called CH505 TF chTrimer in healthy adults. The vaccine is combined with substances to see if it helps the immune system produce strong antibodies. The goal is to ensure the vaccine is safe and effective.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
52 Participants Needed
PanChol Vaccine for Cholera
Boston, MassachusettsThis study is a first-in-human, Phase 1 study of the safety, tolerability, and immunogenicity of PanChol in healthy volunteers. There will be three modules in this clinical trial assessing dosing, safety, and immunogenicity:
1. a fixed dose-ranging module,
2. an adaptive dose-finding/optimization module, and
3. a placebo-controlled expansion module.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunosuppressive Condition, GI Disorder, Cholera History, Others
Must Not Be Taking:Immunosuppressants, Antibiotics, Tetracyclines, Aminoglycosides
53 Participants Needed
AOC 1044 for Duchenne Muscular Dystrophy
Worcester, MassachusettsAOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping.
Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers.
Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:7 - 55
Sex:Male
64 Participants Needed
Experimental Drug for Leukemia Post-Stem Cell Transplant
Boston, MassachusettsThis is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Cardiac Disease, Significant Infection, Prior HCT, Others
63 Participants Needed
VLP Peanut for Peanut Allergy
Boston, MassachusettsThis phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Asthma, Anaphylaxis, Others
46 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do clinical trials in Boston, MA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Boston, MA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Boston, MA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Boston, MA ?
Most recently, we added AL001 for Pharmacokinetics, NAM + NMN for Healthy Adults and Vaccine Regimen for HIV Prevention to the Power online platform.